Cystatin C modulates cerebral beta-amyloidosis
Stephan A Kaeser1, Martin C Herzig, Janaky Coomaraswamy
1Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Otfried-Müller Strasse 27, D-72076 Tübingen, Germany.
Nature Genetics
|November 21, 2007
Summary
Genetic variations in the CST3 gene impact cystatin C levels, influencing Alzheimer's disease risk. Lower cystatin C is linked to increased susceptibility, while higher levels may reduce amyloid-beta deposition.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- The CST3 gene encodes cystatin C, a protein implicated in neurodegenerative diseases.
- A specific allele (Thr25) of CST3 is associated with reduced cystatin C secretion and increased Alzheimer's disease susceptibility.
Purpose of the Study:
- To investigate the role of cystatin C in Alzheimer's disease pathogenesis.
- To determine if cystatin C can modulate amyloid-beta deposition and fibril formation in the brain.
Main Methods:
- Overexpression of human cystatin C in the brains of APP-transgenic mice.
- Biochemical assays to assess amyloid-beta deposition and fibril formation.
- In vitro binding assays between cystatin C and amyloid-beta.
Main Results:
- Overexpression of cystatin C significantly reduced cerebral amyloid-beta deposition in APP-transgenic mice.
- Cystatin C was found to bind directly to amyloid-beta.
- Cystatin C inhibited the in vitro fibril formation of amyloid-beta.
Conclusions:
- Cystatin C plays a protective role against amyloid-beta deposition in the brain.
- Concentrations of cystatin C may influence the risk of cerebral amyloidosis.
- Cystatin C represents a potential target for Alzheimer's disease genetic risk assessment and therapeutic strategies.


